Replies

https://patents.justia.com/patent/10130701

Coronavirus
Jul 23, 2015 - THE PIRBRIGHT INSTITUTE
The present invention provides a live, attenuated coronavirus comprising a variant replicase gene encoding polyproteins comprising a mutation in one or more of non-structural protein(s) (nsp)-10, nsp-14, nsp-15 or nsp-16. The coronavirus may be used as a vaccine for treating and/or preventing a disease, such as infectious bronchitis, in a subject.

https://www.pirbright.ac.uk/partnerships/our-major-stakeholders

The Pirbright Institute is a publicly funded private company. We have a diverse range of major stakeholders, and receive strategic funding from the Biotechnology and Biological Sciences Research Council (BBSRC) which is part of UK Research and Innovation (UKRI).

Our major stakeholders are:

Biotechnology and Biological Sciences Research Council (BBSRC)
UK Department for the Environment, Food and Rural Affairs (Defra)
Wellcome Trust, Medical Research Council (MRC) and other research funding agencies
International funding and disease control agencies, such as OIE, WHO, the European Commission, Bill and Melinda Gates Foundation
Industrial producers of veterinary vaccines and antivirals
Farmers and livestock keepers